Home > Search Results: Vicario, Rocio
  Search Tips
Simple Search
Search collections:
Sort by: Display results: Output format:
UAB Digital Repository of Documents 3 records found  Search took 0.00 seconds. 
1.
14 p, 6.9 MB Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer / Hergueta-Redondo, Marta (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ; Sarrio, David (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ; Molina-Crespo, Ángela (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ; Vicario, Rocío (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Bernadó Morales, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Martínez, Lidia (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ; Rojo-Sebastián, Alejandro (Pathology Department, MD Anderson Cancer Center, Madrid, Spain) ; Serra-Musach, Jordi (Institut d'Investigació Biomèdica de Bellvitge) ; Mota, Alba (Translational Research Laboratory, MD Anderson Internacional Foundation, Madrid, Spain) ; Martínez-Ramírez, Ángel (Cytogenetics Department, MD Anderson Cancer Center, Madrid, Spain) ; Castilla, Maria Ángeles (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; González-Martin, Antonio (Oncology Department, MD Anderson Cancer Center, Madrid, Spain) ; Pernas, Sonia (Institut d'Investigació Biomèdica de Bellvitge) ; Cano, Amparo (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ; Cortés, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Nuciforo, Paolo. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Palacios, José (Hospital Universitario Ramón y Cajal (Madrid)) ; Pujana, Miguel Ángel (Institut d'Investigació Biomèdica de Bellvitge) ; Arribas, Joaquín V (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Moreno-Bueno, Gema (Translational Research Laboratory, MD Anderson Internacional Foundation, Madrid, Spain) ; Universitat Autònoma de Barcelona
Around, 30-40% of HER2-positive breast cancers do not show substantial clinical benefit from the targeted therapy and, thus, the mechanisms underlying resistance remain partially unknown. Interestingly, ERBB2 is frequently co-amplified and co-expressed with neighbour genes that may play a relevant role in this cancer subtype. [...]
2016 - 10.18632/oncotarget.10787
Oncotarget, Vol. 7 (july 2016) , p. 56295-56308  
Detailed record - Creative Commons
2.
10 p, 1.9 MB High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy / Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Thyparambil, Sheeno (OncoPlex Diagnostics. USA) ; Aura, Claudia (Vall d'Hebron Institut d'Oncologia) ; Garrido-Castro, Ana (Hospital Universitari Vall d'Hebron) ; Vilaro, Marta (Vall d'Hebron Institut d'Oncologia) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Jimenez, José (Vall d'Hebron Institut d'Oncologia) ; Vicario, Rocío (Vall d'Hebron Institut d'Oncologia) ; Cecchi, Fabiola (OncoPlex Diagnostics. USA) ; Hoos, William (OncoPlex Diagnostics. USA) ; Burrows, Jon (OncoPlex Diagnostics. USA) ; Hembrough, Todd (OncoPlex Diagnostics. USA) ; Ferreres Piñas, Joan Carles (Hospital Universitari Vall d'Hebron) ; Pérez-Garcia, José (Hospital Universitari Vall d'Hebron) ; Arribas, Joaquín Vicente (Institució Catalana de Recerca i Estudis Avançats) ; Cortés, Javier (Hospital Universitari Vall d'Hebron) ; Scaltriti, Maurizio (Memorial Sloan Kettering Cancer Center) ; Universitat Autònoma de Barcelona
Introduction: Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2 treatments. [...]
2016 - 10.1016/j.molonc.2015.09.002
Molecular Oncology, Vol. 10, núm 1 (January 2016) , p. 138-147  
Detailed record - Creative Commons
3.
120 p, 6.5 MB Immunotherapy against HER2-positive breast cancers / Vicario, Rocío ; Arribas, Joaquín V., , dir. (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular
El 20% de los tumores mamarios sobre expresan el receptor de tirosina quinasa HER2, debido a su amplificación génica, tanto dentro de los cromosomas (HSR) como fuera ellos (DM). Se sabe muy poco acerca de la respuesta clínica o el rol en resistencia a terapias de estos patrones de amplificación. [...]
Twenty percent of breast tumors are characterized by the overexpression of the receptor tyrosine kinase HER2, due to amplification of the gene, either within the chromosome (HSR) or outside as extrachromosomal entities (DM). [...]
[Bellaterra] : Universitat Autònoma de Barcelona, 2017  
Detailed record - Creative Commons

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with